Our goal in this continuing Program Project is still to facilitate the transfer of basic science information from the laboratory to help deal with clinical problems in breast cancer, but our focus broadens from primarily prognostic and mechanistic considerations in two directions. First, we will study the molecular correlates of the developmental stages in early breast cancer, to provide not only greater understanding of how the full malignant phenotype is acquired, but also greater clinical ability to distinguish and thus to treat those benign or early malignant lesions destined to cause serious trouble. Second, at the other end of the clinical course, we will be dissecting the components of growth factor pathways as potential targets of new treatment strategies and testing such strategies directly in preclinical model systems. The projects will study: 1) the problem of how best to integrate both new and existing prognostic factors into a coherent assessment of risk for individual patients, comparing expanded forms of the traditional Cox multivariate analysis with newer recursive partitioning and artificial intelligence (neural network) approaches; 2) the occurrence of mutations and variants in the functional domains of the steroid receptor genes, which could result in failures to respond to hormone manipulation even though receptor is present, or in failure to detect receptor, or even in an oncogene-like receptor variant which would stimulate the tumor cell even in the absence of hormone; 3) potential molecular markers -- activated oncogenes, proliferation markers, antigens associated with metastatic behavior, etc.--in well defined early and later lesions at several stages, in order to see which markers might identify high risk lesions and to learn more about the evolutionary pathway (or pathways) by which breast cancer progresses; 4) antigens associated with proliferation as new prognostic as new prognostic markers; 5) TGFalpha as an autocrine mediator of estrogen action, as a factor in the development of hyperplastic lesions in transgenic mice expressing a TGFalpha gene (and/or an EGF-R gene) in the mammary glands, and as a target for inhibiting malignant progression; 6) the insulin-like growth factor (IGF) system, especially the receptors, IGFRI and IGFRII and the IGF binding proteins, as targets for blocking breast cancer growth and tumorigenesis. These projects will all be supported by a tumor/data network core function, flow cytometry, factor assay, and tissue culture core laboratories, and an administrative core. Many of the factors and markers studied in these interactive projects will have important clinical significance. Indeed, our major effort will be to help oncologists integrate and appropriately utilize basic science information in the 1990's in diagnostic and treatment strategies for the breast cancer patient.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA030195-13
Application #
3093371
Study Section
Special Emphasis Panel (SRC (I1))
Project Start
1981-07-15
Project End
1997-04-30
Budget Start
1993-05-01
Budget End
1994-04-30
Support Year
13
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Park, Jun Hyoung; Vithayathil, Sajna; Kumar, Santosh et al. (2016) Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep 14:2154-2165
Pathiraja, Thushangi N; Nayak, Shweta R; Xi, Yuanxin et al. (2014) Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med 6:229ra41
Zhang, Yi; Tseng, Chun-Chih; Tsai, Yuan-Li et al. (2013) Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One 8:e80071
Machado, Heather L; Kittrell, Frances S; Edwards, David et al. (2013) Separation by cell size enriches for mammary stem cell repopulation activity. Stem Cells Transl Med 2:199-203
Zhang, Xiaomei; Claerhout, Sofie; Prat, Aleix et al. (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73:4885-97
Boone, David N; Lee, Adrian V (2012) Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog 17:161-73
Casa, Angelo J; Potter, Adam S; Malik, Simeen et al. (2012) Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat 132:61-73
Creighton, Chad J (2012) Molecular classification and drug response prediction in cancer. Curr Drug Targets 13:1488-94
Pathiraja, Thushangi N; Shetty, Priya B; Jelinek, Jaroslav et al. (2011) Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res 17:4177-86
Heckman-Stoddard, B M; Vargo-Gogola, T; Herrick, M P et al. (2011) P190A RhoGAP is required for mammary gland development. Dev Biol 360:1-10

Showing the most recent 10 out of 260 publications